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Abstract
Objective—Declines in cervical cancer incidence and mortality in Canada and in the United 
States have been widely attributed to the introduction of the Papanicolaou (Pap) test. This article 
reviews changes in screening and introduction of HPV vaccination.
Method—Sentinel events in cervical cancer screening and primary prevention through HPV 
vaccination in the US and Canada are described.
Results—Despite commonalities, cervical cancer screening and prevention differ between the 
two countries. Canada has a combination of opportunistic and organized programs at the 
provincial and territorial level, while the US has opportunistic screening and vaccination systems. 
In the US, the HPV test along with the Pap test (co-testing) is part of national recommendations 
for routine cervical cancer screening for women age 30 and older. Co-testing is not being 
considered anywhere in Canada, but primary HPV testing is currently recommended (but not 
implemented) in one province in Canada.
Conclusion—Many prevention strategies are available for cervical cancer. Continued public 
health efforts should focus on increasing vaccine coverage in the target age groups and cervical 
cancer screening for women at appropriate intervals. Ongoing evaluation will be needed to ensure 
appropriate use of health resources, as vaccinated women become eligible for screening.
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Background
In the United States and Canada, cervical cancer screening is a public health success 
(Centers for Disease Control and Prevention, 2011b; Public Health Agency of Canada, 
2012). Declines in cervical cancer incidence and mortality in both countries have been 
attributed to the introduction of the Papanicolaou (Pap) cytology test, but declines have 
recently leveled off and disparities continue (Freeman and Wingrove, 2005). The United 
States (U.S. Cancer Statistics Working Group, 2010) and Canada (Canadian cancer society's 
steering committee on cancer statistics, 2012) have, respectively, approximately 12,400 and 
1350 cases of cervical cancers diagnosed and 4000 and 390 deaths annually.
While screening with a Pap test remains an important prevention tool, several key 
developments in cervical cancer prevention have slowly shifted focus from cytology-based 
screening alone to incorporate human papillomavirus (HPV)-based screening with Pap 
testing and HPV vaccination. A sentinel event in 1975, was Dr. zur Hausen's hypothesis that 
HPV was the primary cause of cervical cancer (Fig. 1) (zur Hausen et al., 1975). This laid 
the groundwork for development of HPV-based diagnostics and HPV vaccines in following 
decades. Better understanding of the natural history of cervical cancer led to more refined 
screening parameters and options for prevention. While considerable progress has been 
made in the discovery of new technologies related to cervical cancer screening and HPV 
vaccination, challenges remain in making public health prevention of cervical cancer more 
efficient.
Natural history
HPV infection is common, but cervical cancer is comparatively rare and usually slow to 
develop. Almost all sexually active persons will be infected with HPV at least once in their 
lifetime (Weinstock et al., 2004). Most HPV infections clear within a few years (Rodriguez 
et al., 2008). Screening detects many lesions, but most regress, especially low grade 
squamous intraepithelial lesions (LSIL) and atypical cells of undetermined significance 
(ASC-US), confirming that not all lesions need to be treated (Ostor, 1993). Integration of 
HPV and persistence over time, not merely infection, leads to development of high-grade 
precancers and sometimes invasive cervical cancer (Schiffman et al., 2011). Of the 14 
oncogenic HPV types, HPV 16 and to a lesser degree, HPV 18 are considered the HPV 
types that progress most rapidly and most often from infection to significant lesions 
(Schiffman et al., 2011).
HPV-based screening
HPV testing identifies individuals at increased risk of developing high-grade cervical 
precancer or cancer, and has been evaluated as a screening test with cytology (co-testing), as 
a stand-alone screening test (primary HPV screening), and as part of management and 
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surveillance strategies. Although invasive cervical cancer is rare in screened populations, 
false-negative screening cytology results may be responsible for up to 30% of invasive 
cervical cancers (Spence et al., 2007). HPV testing has a higher sensitivity but lower 
specificity (i.e. more false-positive test results) than cytology in the detection of high-grade 
lesions (Moyer and USPSTF, 2012).
Available HPV tests
The most commonly used HPV test in the United States and Canada has been the Digene 
(i.e. Qiagen Inc., Valencia CA) Hybrid Capture 2 (HC2) test (Hogarth et al., 2012). In the 
last 5 years, additional tests have been approved by the US Food and Drug Administration 
(FDA) and Health Canada (HC) for detecting clinically significant levels of 13–14 high-risk 
HPV types (see Table 2).
HPV test use in the United States
Although the first HPV test was FDA-approved in 1988, the HC2 test was only FDA-
approved in 1999 for follow-up of ASC-US cytology to identify women who may benefit 
from immediate colposcopy (Fig. 1). Shortly thereafter, the ASC-US, LSIL (ALTS) trial 
confirmed the efficacy of HPV testing as a triage method for women with ASC-US Pap test 
results, increasing the use of HPV testing (Solomon et al., 2001). Guidelines from the 
American Society for Colposcopy and Cervical Pathology and the American College of 
Obstetricians and Gynecologists (ACOG) recommended using the HPV test for ASC-US 
management and in other less common scenarios (2003;Wright et al., 2002). In 2003, the 
HC2 High-Risk test was FDA-approved for screening women ≥ 30 years as a co-test. ACOG 
and American Cancer Society (ACS) recommended either co-testing or cytology alone, both 
at a 3-year interval. In 2009, ACOG recommended starting screening at age 21, since lesions 
among younger women are likelier to regress and treatment may cause adverse pregnancy 
outcomes. In 2012, because of the high negative predictive value of an HPV test, ACS and 
ACOG recommended co-testing as the preferred option for screening at a 5-year interval 
(American College of Obstetricians and Gynecologists, 2009; Saslow et al., 2012) The 
USPSTF released new recommendations in 2012 and for the first time, also included the 
option of co-testing as a screening strategy with similar intervals (i.e. 5-year interval for co-
testing or 3-year interval with cytology alone) (Moyer and USPSTF, 2012). Despite several 
randomized clinical trials evaluating the efficacy of primary HPV testing, current U.S. 
guidelines do not support primary HPV testing alone, because of limited evidence and 
concerns about the high number of referrals for colposcopy. Both USPSTF and ACS 
guidelines mention a potential role for primary HPV testing, most likely in the context of an 
organized screening system. Guidelines also agree that adequately screened women over age 
65 can discontinue screening. Thus, current guidelines from all organizations are consistent 
with regards to starting and stopping screening, intervals, and HPV co-testing.
HPV test use in Canada
In 1995, the first recommendation about HPV testing in Canada counseled against its use 
(Johnson and Canadian Task Force on the Periodic Health Examination, 1995). The 2003 
Pan-Canadian Forum on Cervical Cancer Prevention and Control recommended HPV testing 
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for triage of abnormal results and primary screening, but the recommendation was not 
implemented in public health programs (Stuart et al., 2004). The 2007 Canadian consensus 
guidelines of the Society of Obstetricians and Gynecologists of Canada recommended type-
specific HPV testing within an appropriate algorithm for eligible women (Provencher DM, 
2007). Triage of HPV DNA testing is recommended for women ≥ 30 years with ASC-US 
and only as an adjunct to cervical cytology, to reduce the false-positive rate of conventional 
cytology and increase the negative predictive value of testing (HPV Consensus Guidelines 
Committee, 2007). Since 2005, Ontario has recommended HPV testing for triage of ASC-
US Pap tests and in 2012, was the first province to also recommend primary HPV testing for 
screening (Murphy et al., 2012a,b). However, in Ontario, HPV testing is only funded for 
ASC-US triage for women ≥ 30, not for primary screening, thus most likely only available 
to women willing to pay out of pocket or through private insurance. Recently, the Canadian 
Task Force on Preventive Health Care recommended against routine screening at age<25 
years, routine screening at ages 25–69 years every 3 years, and and that routine screening 
may stop for ≥70 years who have undergone adequate screening (Canadian Task Force on 
Preventive Health Care, 2013). The recommendations do not address screening with HPV 
testing due to insufficient evidence.
Adherence to screening guidelines
In response to screening guidelines, providers have rapidly adopted new tests, but have been 
slow to adopt increased screening intervals. This resistance to interval change could be the 
result of pre-graduate training, disincentives due to loss of reimbursements with longer 
intervals, and lack of well-organized information systems to track screening history and 
ensure patient recall when screening is due. Findings from U.S. national surveys of 
providers and observational data demonstrate that contrary to guidelines, most providers use 
HPV testing with the Pap test annually, and that woman <30 are often tested for HPV (Lee 
et al., 2011; Phelan et al., 2011; Roland et al., 2011; Saraiya et al., 2010; Tatsas et al., 2012).
In the United States, cervical cancer screening prevalence is determined largely from 
national surveys using self-reported data. Approximately 83% of women with an intact 
cervix aged 21–65 years reported being screened in the past 3 years (Centers for Disease 
Control and Prevention, 2012a).Women less likely to receive recommended screening were 
Asian, Hispanic, foreign-born, less-educated, uninsured and those without a usual source of 
care. In Canada, the percentage of eligible women in the target population who had at least 
one Pap test in a three-year period ranged from 72.4% to 79.6%(Screening Performance 
Indicators Working Group and Control, 2010). The percentage of eligible women who were 
re-screened within three years after a negative Pap test, called the retention rate, ranged from 
74.6% to 87.1% (Screening Performance Indicators Working Group and Control, 2010).
HPV vaccination
Two vaccines are licensed for use in the United States and Canada, quadrivalent HPV 
vaccine (Gardasil, Merck & Co, Inc.), and bivalent HPV vaccine (Cervarix, 
GlaxoSmithKline). Quadrivalent vaccine is directed against two oncogenic types, HPV 16 
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and 18, and two nononcogenic types, HPV 6 and 11. The bivalent vaccine is directed against 
HPV 16 and 18.
HPV vaccination in the United States
Quadrivalent HPV vaccine was licensed by the FDA in June 2006 for use in females aged 
9–26 years (Markowitz et al., 2007). In October 2009, the bivalent vaccine was licensed for 
use in females aged 10–25 years (Centers for Disease Control Prevention, 2010). Following 
licensure by FDA, national recommendations for vaccine use are made by the Advisory 
Committee on Immunization Practices (ACIP) (Fig. 2) (Smith et al., 2009). ACIP considers 
many factors in making recommendations, including efficacy and safety, epidemiology and 
burden of disease, acceptability and cost effectiveness.
In June 2006, ACIP recommended routine vaccination of females aged 11–12 years with 
quadrivalent HPV vaccine (Markowitz et al., 2007). This age was selected to reach girls 
prior to sexual initiation, and to allow incorporation of HPV vaccine into the adolescent 
vaccination schedule. HPV vaccine was also recommended for previously unvaccinated 
females aged 13–26 years. When bivalent HPV vaccine was licensed by FDA in 2009, ACIP 
updated recommendations stating that either HPV vaccine is recommended for females.
In October 2009, quadrivalent HPV vaccine was licensed by FDA for use in males aged 9–
26 years for prevention of genital warts. When data from a sub-study in men who have sex 
with men (MSM) demonstrated efficacy for prevention of vaccine type-related anal 
precancer lesions (Palefsky), quadrivalent HPV vaccine received an indication for 
prevention of anal cancer in both males and females (December 2010). After licensure of the 
vaccine for males, ACIP provided guidance that the vaccine may be used in males ages 9–26 
years, but did not include vaccine for males in the routine immunization schedule (Centers 
for Disease Control and Prevention, 2010). Two years later, after review of additional data 
including vaccine efficacy for protection against anal precancers in males, the burden of 
HPV-associated disease in males, the status of the female vaccination program, safety and 
cost effectiveness, ACIP recommended routine vaccination of males at age 11–12 years, and 
vaccination through age 21 years for those not previously vaccinated (Centers for Disease 
Control and Prevention, 2011a; Chesson et al., 2011). For MSM and immunocompromised 
persons, vaccination is recommended through age 26 years for those not previously 
vaccinated.
Vaccines recommended by ACIP are usually included in the Vaccines for Children Program 
(VFC), which supplies providers with federally purchased vaccines as recommended for use 
among eligible children ages 0–18 years (Centers for Disease Control and Prevention). Both 
the quadrivalent and bivalent HPV vaccines were included in the VFC program for females 
at the time recommendations were made for each vaccine. Quadrivalent HPV vaccine for 
males was included in the VFC program in October 2009. Heath insurance usually covers 
vaccines routinely recommended by ACIP.
The progress of the immunization program in the United States is measured by the National 
Immunization Survey (NIS), which uses provider-verified records to determine vaccine 
coverage. Since 2006, national and state-specific vaccine coverage has been measured by 
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NIS among 13–17 year olds. HPV vaccine initiation (at least one dose) among females 
increased from 25% in 2007 to 53% in 2011. In 2011, coverage with 3 doses of HPV 
vaccine was 35% among females and ranged by state (16%–57%) (Centers for Disease 
Control and Prevention, 2012b).
HPV vaccination in Canada
In July 2006, quadrivalent vaccine was approved by HC for use in females 9–26 years of age 
(Fig. 1). In February 2010, bivalent vaccine was approved for use in females 9–25 years of 
age (GSK). Also in February 2010, quadrivalent vaccine was approved for males 9–26 years 
of age for the prevention of HPV 6, 11, 16, and 18 infections as well as genital warts. In 
April 2011, quadrivalent vaccine was approved for use in females 9–45 years of age, and in 
May 2011, quadrivalent vaccine was approved for use in persons aged 9–26 years of age for 
the prevention of anal cancer and anal precancer lesions (Merck Canada Inc., 2012).
Following approval by HC, national recommendations for vaccine use are made by the 
National Advisory Committee on Immunization (NACI) (Fig. 3). NACI recommends 
bivalent or quadrivalent vaccines for females 9–26 years of age. Quadrivalent vaccine is 
recommended for males 9–26 years of age and males ≥9 years of age who have sex with 
men. Quadrivalent vaccine or bivalent vaccine may be administered to females older than 
(National Advisory Committee on, 2007, 2012; National Advisory Committee on 
Immunization (NACI), 2007). Provincial and territorial public health authorities adapt NACI 
recommendations into local programs, explaining differences in vaccine use across Canada 
(Table 1). These programs identify specific target age groups for the vaccination program. 
Providers can vaccinate patients outside the free programs of their province or territory but 
within HC licensures; patients may be covered by private insurance or pay out-of-pocket.
Coverage rates for completed school-based programs range from 50 to 94% depending on 
the region or the province (Naus and Ogilvie, 2010). For example, rates in Quebec vary 
regionally: for Grade 4, from 66 to 94% (mean 77%), and for Grade 9: 63–93% (mean 
76%). Canadian programs for females of the target age but not reached by the school-based 
program have lower rates of coverage.
Achieving efficiency in cervical cancer prevention
Newer HPV prevention strategies are costlier initially, but may reduce cancers and 
precancers, ultimately reducing morbidity and treatment costs (Goldhaber-Fiebert et al., 
2007). Current guidelines are developed using evidence-based methods incorporating 
natural history, epidemiology, burden of disease, cost-effectiveness, sustainability, 
feasibility and acceptability.
Guidelines for cervical cancer screening among fully-vaccinated girls have not yet changed 
in Canada or in the United States, because coverage is not optimal and few actual changes in 
HPV prevalence or HPV-based outcomes have been documented (e.g., decreases in high-
grade precancers like CIN2/3) (Saslow et al., 2012). With decreased prevalence of HPV 
16/18 infection, decreases in precancers may be observed sooner in younger women since 
HPV16 attributable precancers and cancers develop more rapidly and are more frequent than 
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those due to other HPV types. Furthermore, the positive predictive value of cytology-based 
testing will be impacted, possibly resulting in HPV-genotype-specific screening strategies 
(Castle et al., 2008; Saslow et al., 2012; Wheeler et al., 2009).
Increase adherence to screening guidelines
Current evidence-based cervical cancer screening guidelines are targeted towards average-
risk women who could benefit the most from screening, (Table 3) by: 1) beginning 
screening at age 21, minimizing discovery of frequently self-limiting lesions which need 
colposcopic assessment and which might result in adverse birth outcomes; 2) stopping 
screening at recommended ages (65 years in US and 65–70 years in Canada) among women 
with a history of adequate screening or after a total hysterectomy for benign reasons; and, 3) 
adopting HPV testing starting at a later age, to increase sensitivity while also increasing time 
between screening, lowering the number of lifetime screenings. More provinces in Canada 
are considering primary HPV testing. As screening becomes less frequent, the available time 
in a visit may be used to provide other recommended evidence-based, age-appropriate 
screening or counseling (Institute of Medicine, 2011; Stormo et al., 2011, 2012).
Some European countries have achieved efficiency and favorable outcomes through 
organized screening programs. Many countries with organized screening programs, 
including Canada, have not adopted co-testing, citing this strategy as cost-ineffective (Ronco 
et al., 2012). Given the lower specificity of the HPV test, overtreatment is a concern, thus 
recommendations generally use primary HPV testing among women 30 years of age and 
older, with a triage cytology test before referral to colposcopy. The Netherlands is 
contemplating adoption of primary HPV testing with cytology triage (Meijer, 2011). On the 
other hand, in Finland there is considerable debate on whether a more efficient screening 
program could be achieved by limiting opportunistic screening, limiting cytology-based 
screening to women 25–35 years of age, and then using HPV testing as a primary screening 
test for older women (Niemenen, 2012). A community-based randomized clinical trial found 
that HPV testing may lead to over-diagnosis of self-limiting low-grade disease leading to 
unnecessary procedures, raising concerns about switching from cytology-based screening to 
HPV-based screening, especially in an organized infrastructure where invasive cancer is rare 
and cytology sensitivity is high (Malila et al., 2013).
Ensuring screening coverage of women at highest risk of getting cervical 
cancer
In the United States and Canada, the population at greatest risk of getting and dying from are 
women who have irregular or no access to screening. This includes immigrant women, poor 
women, women belonging to certain racial/ethnic groups (e.g. Hispanic, Asian/Pacific 
Islander, Indigenous populations), and women from rural or isolated areas (e.g. Appalachia, 
Border, Deep South) (Freeman and Wingrove, 2005; Horner et al., 2011; Vasilevska et al., 
2012).
Both U.S. and Canadian systematic reviews have found that client-based interventions (e.g., 
client reminders, small media, one-on-one education) improve screening rates for cervical 
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cancer (Community Preventive Services Task Force, 2012; Sabatino et al., 2012; Brouwers 
et al., 2011a,b). Effective provider-based interventions include prompts to inform health care 
providers that a client should present for screening (called a “reminder”) or that the client is 
overdue for screening (called a “recall”). Provider assessment and feedback interventions 
evaluate provider performance in delivering or offering screening to clients (assessment) and 
present providers with information about their performance in providing screening services 
(feedback). Feedback may describe the performance of a group of providers or an individual 
provider, and may be compared with a goal or standard (Community Preventive Services 
Task Force, 2012).
Organized screening programs with centralized data collection and follow-up strategies have 
shown greater reductions of cervical cancer than opportunistic screening, which often 
excludes women with no connection to a primary care organization (Albrow et al., 2012). 
The United States has largely relied on the model of more frequent screening to allow for 
lapses in follow up, feedback, and communication inherent in opportunistic screening 
(Habbema et al., 2012). As more organized systems are established for routine clinical 
preventive services, adherence to guideline-based screening can be achieved. In Canada, 
there is a mix of organized and opportunistic screening; provinces with centralized systems 
are opting for more efficient screening algorithms.
In spite of provider reminder and recall systems and organized screening programs, certain 
women will remain at higher risk of not getting screened in a clinical setting, either due to 
loss of privacy, having a male provider, or other barriers. Self-sampling techniques have 
been shown to be similar to physician-collected tests and can increase access for women 
with low access to care (Cerigo et al., 2012; Scarinci et al., 2010; Stewart et al., 2007). 
However, organized screening systems must be in place to ensure proper follow-up in terms 
of interval for screening as well as follow up of abnormal results of these women.
Achieving high vaccine coverage
A variety of factors impact vaccine coverage, including delivery systems, financing and 
acceptability. In the United States most vaccinations are delivered by primary care providers 
during preventive healthcare visits. As for all vaccinations, a strong provider 
recommendation has been found to be important for HPV vaccination (Dorell et al., 2011); 
lack of strong provider recommendations results in many missed opportunities. Use of 
reminder systems could also help increase coverage (Suh et al., 2012). In Canada, the HPV 
vaccination program is primarily school-based for the target age group, resulting in higher 
coverage. School-based programs in Canada (even for adolescents) have a long history, and 
HPV vaccines have generally been added to other vaccines already given at such ages.
Conclusion
Cervical cancer screening and follow-up alone are estimated to cost $6.6 billion annually in 
the United States (Chesson et al., 2012). Screening in the US is costly compared to other 
countries for several reasons: rapid adoption of expensive new technologies, opportunistic 
screening, private insurance reimbursement not tied to evidence based guidelines, and 
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provider fear of litigation. Compared to the Netherlands which has observed a similar 
decrease in cervical cancer mortality, a woman in the United States has approximately 3 to 4 
times as many Pap tests over her lifetime (Habbema et al., 2012).
With the advent of HPV vaccines, the United States and Canada have both primary as well 
as secondary prevention strategies for cervical cancer. In Canada, the HPV vaccination 
program is primarily school-based for the target age group, resulting in generally high 
coverage. Continued public health efforts should be directed at increasing vaccine coverage 
in the target age groups and at cervical cancer screening for women at highest risk. 
Vaccinated women should be aware of the need for continued cervical cancer screening at 
recommended intervals. As vaccine coverage increases and vaccinated women move into 
ages targeted for screening, further evaluation of screening programs will be needed to 
ensure appropriate use of health resources.
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Evolution of HPV testing in Canada and the United States. Footnotes: US=United States. 
CAN=Canada. FDA=US Food and Drug administration. HC=Health Canada. USPSTF=US 
Preventive Services Task Force. ASC-US=Atypical squamous cells of undetermined 
significance. HPV=Human Papillomavirus. HPV testing was first recommended for triage of 
ASC-US lesions by the American Society for Colposcopy and Cervical Pathology in 2001. 
The American Cancer Society and American College of Obstetricians and Gynecologists 
recommended HPV tests as an option for screening women 30 years and older starting in 
2003. The US Preventive service Task Force made a similar recommendation in 2012. The 
Pan-Canadian Forum on Cervical Cancer Prevention and Control first recommended HPV 
testing for triage of ASCUS lesions in Canada in 2003. The Society of Obstetricians and 
Gynecologists of Canada made a similar recommendation in 2007. SOURCES: Cox, JT. 
History of the use of HPV testing in cervical screening and in the management of abnormal 
cervical screening results. Journal of Clinical Virology 2009;45:S3–S12. Centers for Disease 
Control and Prevention. Cervical Cancer Screening Guidelines for Average-Risk Women. 
Available at http://www.cdc.gov/cancer/cervical/pdf/guidelines.pdf. Accessed November 6, 
2012. FDA. U.S. Food and Drug Administration website. Available at www.fda.gov. 
Accessed November 6, 2012.
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United States: evolution of recommendations for HPV vaccination from the Advisory 
Committee on Immunization Practice (ACIP). Footnotes: Quadrivalent (HPV 6,11,16,18) 
vaccine; Bivalent (HPV 16,18) vaccine. *Can be given starting at 9 years of age;. **For 
MSM and immunocompromised males, quadrivalent HPV vaccine through 26 years of age. 
SOURCES: Centers for Disease Control and Prevention. Quadrivalent Human 
Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization 
Practices (ACIP), 2007. MMWR Recomm. Rep. 56, 1–24. Centers for Disease Control 
Prevention, 2010. FDA licensure of bivalent human papillomavirus vaccine (HPV2, 
Cervarix) for use in females and updated HPV vaccination recommendations from the 
Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rep. 
59, 626–629. Centers for Disease Control and Prevention, 2011. Recommendations on the 
use of quadrivalent human papillomavirus vaccine in males—Advisory Committee on 
Immunization Practices (ACIP), 2011. MMWR Morb. Mortal. Wkly Rep. 60, 1705–1708.
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Canada: Evolution of Recommendations for HPV Vaccination from the National Advisory 
Committee on Immunization (NACI)*. Footnotes: Quadrivalent (HPV 6,11,16,18) vaccine; 
Bivalent (HPV 16,18) vaccine. *Recommendations are adapted by provincial and territorial 
programs. *Grade A for quadrivalent and Grade B for bivalent. National Advisory 
Committee on Immunization (NACI). Statement on human papillomavirus vaccine. An 
Advisory Committee Statement (ACS). Can Commun Dis Rep 2007;33 ACS-2: 1–31. 
Advisory Committee Statement (ACS) National Advisory Committee on Immunization 
(NACI) Update on Human Papillomavirus (HPV) Can Commun Dis Rep 2012;38 ACS-1:1–
62. Note: NACI makes recommendations, but it is up to the various provincial and territorial 
authorities to adapt them to their specific vaccine programs.
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Table 1
HPV immunization programs in Canada.
Province/territory Routine 
schedule





Catch-up programs (date of 
implementation)
Coverage
British Columbia Grade 6 September 2008 Grade 9 (2008–2011) 62%
Alberta Grade 5 September 2008 Grade 9 (2009–2012) 50–60%
Saskatchewan Grade 6 September 2008 Grade 7 (2008–2009) 58–66%
Manitoba Grade 6 September 2008 52–61%
Ontario Grade 8 September 2007 53%
Quebec Grade 4* September 2008 9–17 years oldwith school based program in 
Grade 4 and Grade 9 and “catch up” by 
participating clinics (2008–2013)







New Brunswick Grade 7 September 2008 Grade 8 (2008–2009) n/a
Nova Scotia Grade 7 September 2007 Grade 10 (2009–2010 only) 85%
Grade 8 (2010–2011 only)
Prince Edward Island Grade 6 September 2007 Grade 9 (2009–2010 only) 85%
Newfoundland and Labrador Grade 6 September 2007 Grade 9 (2008–2010) 85%
Northwest Territories Grade 4 September 2009 Grades 11 & 12 (2009–2010)
Grades 10 & 11 (2010–2011)
Grades 9 & 10 (2011–2012)
Grade 9 (2012–2014)
Yukon Grade 6 September 2009 Grades 7 & 8
Nunavut Grade 6 March 2010
Source:
Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) Update on Human Papillomavirus (HPV) CCDR. 
2012;38 ACS-1:1–62.
British Columbia: Naus M, Ogilvie G. Human papillomavirus vaccine program in British Columbia: A good start with room for improvement. 
BCMJ, Vol. 52, No. 2, March 2010, p. 95
BC Centre for Disease Control.
Québec: Flash vigie, bulletin québécois de vigie et d'intervention en maladies infectieuses. Vol. 7, no. 7: 3–4.
Coverage rates provided Julie Laroche, Public Health Agency of Canada and appropriate provincial and territorial HPV immunization.
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Table 2
Currently available HPV tests in the United States and Canada.*
Test Manufacturer Method HPV types detected Information obtained 
from test
Hybrid capture 2 Qiagen (Valencia, California) Signal amplification 13 high risk HPV DNA types Indication of a high risk 
HPV type present
Cervista™ HPV HR 
test
Hologic (Bedford, MA) Probe amplification 14 High Risk HPV DNA 
types




Hologic (Bedford, MA) Probe amplification HPV 16/18 (DNA) Indication of presence of 
HPV 16/18
Aptima HPV GenProbe (San Diego, CA) Target amplification 14 high risk HPV types 
(RNA/E6/E7)
Indication of a high risk 
HPV type present
Cobas 4800 HPV 
test
Roche molecular systems 
(Pleasanton, CA)
Target amplification 14 high risk HPV (DNA/L1 
region)
Indicates which high risk 
is present
*
Approved by FDA in United States or by Health Canada.
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